{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:22Z","timestamp":1794248602116,"version":"4.9.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,21]]},"abstract":"<jats:p>\n                    Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the 2 major types of primary liver cancer, differing significantly in etiology, treatment strategies, and prognosis despite their common hepatic origin. Accurate preoperative differentiation between HCC and ICC is critical for optimizing treatment and improving patient outcomes. However, traditional diagnostic methods, including imaging and tumor markers, have limitations in sensitivity and specificity, necessitating the exploration of novel diagnostic approaches. This retrospective study included 165 patients diagnosed with HCC (n\u2005=\u200587) or ICC (n\u2005=\u200578) between January 2023 and January 2024. Preoperative data, including routine blood tests and tumor markers (e.g., alpha-fetoprotein [AFP], carbohydrate antigen 19-9 [CA19-9], carcinoembryonic antigen [CEA]), were collected. Blood routine parameters, such as white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR), were analyzed. Univariate and multivariate logistic regression analyses were conducted to identify independent diagnostic factors. A predictive model was constructed and its diagnostic performance evaluated using receiver operating characteristic curves. Subgroup analyses were performed to investigate diagnostic efficiency in different patient subsets. AFP and CA19-9 emerged as key tumor markers for differentiating HCC and ICC. AFP levels were significantly higher in HCC patients (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), whereas CA19-9 levels were markedly elevated in ICC patients (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Among blood routine parameters, elevated WBC (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), monocyte count (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005), NLR (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.02), and monocyte ratio (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.012) were associated with an increased risk of ICC, while a higher LMR was protective against ICC (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006). The multivariate logistic regression model demonstrated robust diagnostic accuracy, with an area under the curve (AUC) of 0.791. Subgroup analyses revealed superior diagnostic performance at higher levels of AFP (\u2265200\u2009ng\/mL, AUC\u2005=\u20050.90) and CA19-9 (\u226537 U\/mL, AUC\u2005=\u20050.91). The combination of blood routine parameters and tumor markers demonstrates high diagnostic efficacy in preoperatively differentiating HCC and ICC. Key markers, including AFP and CA19-9, along with inflammatory and immune-related blood parameters such as WBC, NLR, and LMR, significantly enhance diagnostic accuracy. This study provides valuable insights into refining diagnostic strategies and supports individualized treatment planning for patients with primary liver cancer.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000041899","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:23:07Z","timestamp":1743034987000},"page":"e41899","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical value of blood routine and tumor markers in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma"],"prefix":"10.1097","volume":"104","author":[{"given":"Wei","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pathology, Tongling Polytechnic, Tongling, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongling Polytechnic, Tongling, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Physiology, Tongling Polytechnic, Tongling, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, the First Affiliated Hospital of Anhui Medical University, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2090-056X","authenticated-orcid":false,"given":"Shifeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Physiology, Tongling Polytechnic, Tongling, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261109","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes.","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"R2-20261109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"R4-20261109","doi-asserted-by":"crossref","first-page":"1073274817729245","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.","volume":"24","author":"Massarweh","year":"2017","journal-title":"Cancer Control"},{"key":"R5-20261109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma.","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"R6-20261109","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"R7-20261109","doi-asserted-by":"crossref","first-page":"101328","DOI":"10.1016\/j.xcrm.2023.101328","article-title":"Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.","volume":"4","author":"Do","year":"2023","journal-title":"Cell Rep Med"},{"key":"R8-20261109","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00330-021-08188-y","article-title":"Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.","volume":"32","author":"Zhou","year":"2022","journal-title":"Eur Radiol"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"e0240791","DOI":"10.1371\/journal.pone.0240791","article-title":"Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.","volume":"15","author":"Chiu","year":"2020","journal-title":"PLoS One"},{"key":"R10-20261109","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/CH-211145","article-title":"Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: a systematic review and meta-analysis.","volume":"79","author":"Chen","year":"2021","journal-title":"Clin Hemorheol Microcirc"},{"key":"R11-20261109","doi-asserted-by":"crossref","first-page":"1073274817729244","DOI":"10.1177\/1073274817729244","article-title":"Liver-directed therapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.","volume":"24","author":"Kis","year":"2017","journal-title":"Cancer Control"},{"key":"R12-20261109","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1007\/s13277-015-3188-6","article-title":"The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour Biol"},{"key":"R13-20261109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejrad.2017.05.011","article-title":"Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: a preliminary study comparing with 99mTc GSA scintigraphy and signal intensity based parameters.","volume":"92","author":"Nakagawa","year":"2017","journal-title":"Eur J Radiol"},{"key":"R14-20261109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-021-00245-6","article-title":"Hepatocellular carcinoma.","volume":"7","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R15-20261109","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians.","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R16-20261109","doi-asserted-by":"crossref","first-page":"e231208","DOI":"10.1148\/radiol.231208","article-title":"CT rule-in and rule-out criteria for clinically significant portal hypertension in chronic liver disease.","volume":"309","author":"Heo","year":"2023","journal-title":"Radiology"},{"key":"R17-20261109","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1038\/s41598-023-38307-2","article-title":"Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma.","volume":"13","author":"Pomyen","year":"2023","journal-title":"Sci Rep"},{"key":"R18-20261109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semradonc.2018.06.010","article-title":"Hepatocellular carcinoma and intrahepatic cholangiocarcinoma: imaging for diagnosis, tumor response to treatment and liver response to radiation.","volume":"28","author":"Lo","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"R19-20261109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2016.02.001","article-title":"Reciprocal activation between MMP-8 and TGF-\u03b21 stimulates EMT and malignant progression of hepatocellular carcinoma.","volume":"374","author":"Qin","year":"2016","journal-title":"Cancer Lett"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3109\/07853890.2013.823779","article-title":"Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.","volume":"45","author":"Lempinen","year":"2013","journal-title":"Ann Med"},{"key":"R21-20261109","doi-asserted-by":"crossref","first-page":"101573","DOI":"10.1016\/j.clinre.2020.11.004","article-title":"Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.","volume":"45","author":"Ge","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:00:43Z","timestamp":1794247243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041899","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}